Strapped For Cash GenSight Eyes Survival Options
French Firm Pulls Lumevoq Filing
The future of GenSight hangs in the balance following the decision to withdraw its application in Europe for Lumevoq, the company's gene therapy for Leber hereditary optic neuropathy, and worries over a rapidly diminishing cash pile.
